A carregar...
Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series
BACKGROUND: Olaparib, a poly ADP-ribose polymerase (PARP) inhibitor, has proven to be effective and safe as maintenance therapy and multiline therapy in ovarian cancer, especially in patients with BRCA mutations. This study intended to observe the influence of tumor load on the efficacy and safety o...
Na minha lista:
| Publicado no: | J Ovarian Res |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7079537/ https://ncbi.nlm.nih.gov/pubmed/32183851 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13048-020-00629-4 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|